Predictive performance of serum adipsin combined with 25(OH)D for peripheral neuropathy in elderly diabetic patients
Abstract
Objective: Diabetic peripheral neuropathy (DPN) is a common chronic complication in older adults with type 2 diabetes mellitus (T2DM). Early diagnosis is essential for delaying disease progression. This study set out to explore the predictive value of the combined detection of serum adipocytokine adipsin and 25-hydroxyvitamin D [25(OH)D] in elderly DPN patients, and to provide new strategies for early intervention.
Methods: Based on the electronic medical records of our hospital from January 2024 to June 2025, 150 elderly patients with T2DM (104 in DPN group and 57 in non-DPN group) were enrolled. Serum adipsin was detected by ELISA, and 25(OH)D was measured via chemiluminescent immunoassay. The diagnostic efficacy of the combined detection was confirmed by univariate analysis, Logistic regression model, and ROC curves. Disease course and age-stratified subgroup analyses were further carried out.
Results: DPN patients showed higher serum adipsin but lower 25(OH)D levels than non-DPN cases (P<0.05). Adipsin + 25(OH)D detection exhibited an AUC of 0.831 (sensitivity: 64.42%, specificity: 87.72%), higher than single-index predictions. Subgroup analysis indicated superior prediction efficiency of the combined detection in patients with a course of disease ≥6 years (AUC>0.85). According to correlation analysis, adipsin was positively correlated with FPG, HbA1c, and VPT, and negatively correlated with NCV and SCV; while the opposite was true for 25(OH)D.
Conclusion: Serum adipsin combined with 25(OH)D has high predictive value for elderly DPN, and their synergistic effect may be exerted through the "inflammation-oxidative stress-metabolic disorder" axis.
Copyright (c) 2025 Yi Wu, Menglu Li, Yu Cui, Dan Su, Xiaodan Qian, Lidan Tang, Hao Yang, Shan Xu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.